3 US Penny Stocks With Market Caps Under $50M To Watch

In This Article:

As the post-election rally loses steam, major U.S. indexes are showing mixed results, highlighting the ongoing volatility in the market. In such a climate, investors often seek out opportunities that offer both affordability and potential for growth. Penny stocks, though sometimes considered an outdated term, continue to attract attention due to their potential for significant returns when backed by strong financials. Here, we explore three penny stocks that exemplify this balance of financial strength and growth opportunity.

Top 10 Penny Stocks In The United States

Name

Share Price

Market Cap

Financial Health Rating

BAB (OTCPK:BABB)

$0.81915

$6.09M

★★★★★★

RLX Technology (NYSE:RLX)

$1.61

$2.05B

★★★★★★

AsiaFIN Holdings (OTCPK:ASFH)

$1.50

$81.55M

★★★★★★

QuantaSing Group (NasdaqGM:QSG)

$3.08

$161.52M

★★★★★★

PHX Minerals (NYSE:PHX)

$3.40

$125.19M

★★★★★☆

So-Young International (NasdaqGM:SY)

$1.25

$72.53M

★★★★☆☆

Golden Growers Cooperative (OTCPK:GGRO.U)

$4.50

$69.71M

★★★★★★

Better Choice (NYSEAM:BTTR)

$1.95

$3.83M

★★★★★★

Flexible Solutions International (NYSEAM:FSI)

$4.22

$54.16M

★★★★★★

CBAK Energy Technology (NasdaqCM:CBAT)

$0.9278

$87.69M

★★★★★☆

Click here to see the full list of 738 stocks from our US Penny Stocks screener.

Underneath we present a selection of stocks filtered out by our screen.

IRIDEX

Simply Wall St Financial Health Rating: ★★★★★★

Overview: IRIDEX Corporation is an ophthalmic medical technology company that offers laser systems, delivery devices, and consumable instruments for treating sight-threatening eye diseases, with a market cap of $23.46 million.

Operations: The company's revenue segment is entirely derived from its ophthalmology division, generating $49.7 million.

Market Cap: $23.46M

IRIDEX Corporation, with a market cap of US$23.46 million, is navigating challenges typical of penny stocks, including high volatility and recent shareholder dilution. The company remains unprofitable with a negative return on equity and increasing losses over the past five years at 2.3% annually. Recent earnings reports highlight declining sales—US$11.58 million in Q3 2024 compared to US$12.85 million a year ago—and growing net losses. Despite no debt and sufficient short-term assets to cover liabilities, IRIDEX's cash runway is limited to nine months without additional capital infusion, reflecting ongoing financial pressures amid leadership changes.

NasdaqCM:IRIX Financial Position Analysis as at Nov 2024
NasdaqCM:IRIX Financial Position Analysis as at Nov 2024

Pixelworks

Simply Wall St Financial Health Rating: ★★★★★★